<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tassopoulos, N. C.</style></author><author><style face="normal" font="default" size="100%">Tsantoulas, D.</style></author><author><style face="normal" font="default" size="100%">Raptopoulou, M.</style></author><author><style face="normal" font="default" size="100%">Vassiliadis, T.</style></author><author><style face="normal" font="default" size="100%">Kanatakis, S.</style></author><author><style face="normal" font="default" size="100%">Paraskevas, E</style></author><author><style face="normal" font="default" size="100%">Vafiadis, I.</style></author><author><style face="normal" font="default" size="100%">Avgerinos, A.</style></author><author><style face="normal" font="default" size="100%">Tzathas, C.</style></author><author><style face="normal" font="default" size="100%">Manolakopoulos, S.</style></author><author><style face="normal" font="default" size="100%">Ketikoglou, I.</style></author><author><style face="normal" font="default" size="100%">Aggelis, P.</style></author><author><style face="normal" font="default" size="100%">Goritsas, K.</style></author><author><style face="normal" font="default" size="100%">Giannoulis, G.</style></author><author><style face="normal" font="default" size="100%">Hatzis, G. G.</style></author><author><style face="normal" font="default" size="100%">Thomopoulos, K.</style></author><author><style face="normal" font="default" size="100%">Akriviadis, E.</style></author><author><style face="normal" font="default" size="100%">Sypsa, V</style></author><author><style face="normal" font="default" size="100%">Hatzakis, A</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1</style></title><secondary-title><style face="normal" font="default" size="100%">J Viral HepatJ Viral HepatJ Viral Hepat</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of viral hepatitis</style></alt-title><short-title><style face="normal" font="default" size="100%">Journal of viral hepatitisJournal of viral hepatitis</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Antiviral Agents/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepacivirus/classification/drug effects/genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis C, Chronic/*drug therapy/virology</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Interferon alpha-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Interferon-alpha/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Recombinant Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Ribavirin/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Viral/blood</style></keyword><keyword><style  face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style  face="normal" font="default" size="100%">May</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">10</style></volume><pages><style face="normal" font="default" size="100%">189-96</style></pages><isbn><style face="normal" font="default" size="100%">1352-0504 (Print)1352-0504 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">A randomized trial was conducted to assess the efficacy of daily (QD) or thrice weekly (TIW) administration of interferon-alpha (IFN) in high doses in combination with ribavirin (1.0-1.2 g/day) in patients with chronic hepatitis C (CHC) who were nonresponders to previous IFN monotherapy. Interferon was administered as 10 MU IFN (QD or TIW) for 4 weeks, followed by 5 MU IFN (QD or TIW) for 20 weeks, and then by 3 MU IFN (QD or TIW) for 24 weeks. Sustained virological response (SVR) was evaluated in 142 patients who received at least one dose of medication. One-fourth of the patients achieved SVR, 26% of those treated with IFN QD and 25% of those treated with IFN TIW (P = 0.85). For genotype 1 patients, SVR rates were 32.4 and 15.8% for IFN QD and IFN TIW, respectively, whereas for genotype non-1 patients the corresponding SVR rates were 20.6 and 36.4%, respectively (test of homogeneity: P = 0.031). This finding was further confirmed by multivariate logistic regression analysis where a statistically significant interaction (P = 0.012) was found between treatment and HCV genotype indicating that the IFN QD regimen was superior to IFN TIW among genotype 1 patients whereas, among genotype non-1 patients, the two treatments were similar (odds ratio of SVR in IFN QD vs IFN TIW: 3.33 among genotype 1 patients, 95% CI: 1.00-11.14). In conclusion, re-treatment of patients not responding to previous IFN monotherapy with a combination of high daily dose of IFN with ribavirin may be beneficial for genotype 1 infected patients.</style></abstract><accession-num><style face="normal" font="default" size="100%">12753337</style></accession-num><notes><style face="normal" font="default" size="100%">Tassopoulos, N CTsantoulas, DRaptopoulou, MVassiliadis, TKanatakis, SParaskevas, EVafiadis, IAvgerinos, ATzathas, CManolakopoulos, SKetikoglou, IAggelis, PGoritsas, KGiannoulis, GHatzis G, GThomopoulos, KAkriviadis, ESypsa, VHatzakis, AengClinical TrialMulticenter StudyRandomized Controlled TrialResearch Support, Non-U.S. Gov'tEngland2003/05/20 05:00J Viral Hepat. 2003 May;10(3):189-96. doi: 10.1046/j.1365-2893.2003.00406.x.</style></notes><auth-address><style face="normal" font="default" size="100%">Western Attica General Hospital, Athens, Greece.</style></auth-address></record></records></xml>